Clinical Trial

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-12-20; most recent amendment 2026-03-06.
Trial Details
NCT Number NCT05669950
Lead Sponsor H. Lundbeck A/S
Conditions Congenital Adrenal Hyperplasia
Enrollment 42 participants
Start Date 2022-12-19
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-09